2. Search Result
Search Result
Results for "

Pyk2

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

1

Peptides

2

Recombinant Proteins

8

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10459
    PF-562271
    Maximum Cited Publications
    30 Publications Verification

    VS-6062

    		 FAK Pyk2 Cancer
    PF-562271 (VS-6062) is a potent, ATP-competitive and reversible FAK and Pyk2 kinase inhibitor with IC50s of 1.5 nM and 13 nM, respectively .
    PF-562271
  • HY-134570
    ZINC40099027
    3 Publications Verification

    		 FAK Metabolic Disease Inflammation/Immunology
    ZINC40099027 is a selective FAK activator. ZINC40099027 promotes FAK phosphorylation, without activating its paralogs Pyk2 and Src. ZINC40099027 promotes the wound closure of human intestinal epithelial monolayers and the healing of mouse ulcers by activating FAK. ZINC40099027 can be used for diseases related to gastrointestinal mucosal injury research .
    ZINC40099027
  • HY-10460
    PF-431396
    5+ Cited Publications

    		 Pyk2 FAK Cancer
    PF-431396 is an orally active dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor, with IC50 values of 2 nM and 11 nM, respectively [2] .
    PF-431396
  • HY-13203
    NVP-TAE 226
    5+ Cited Publications

    TAE226

    		 FAK Pyk2 IGF-1R Insulin Receptor Apoptosis Endocrinology Cancer
    NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual FAK and IGF-1R inhibitor with IC50s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits Pyk2 and insulin receptor (InsR) with IC50s of 3.5 nM and 44 nM, respectively [2].
    NVP-TAE 226
  • HY-18312
    PF-4618433
    5 Publications Verification

    		 Pyk2 Metabolic Disease
    PF-4618433 is a potent and selective PYK2 inhibitor, with an IC50 of 637 nM. PF-4618433 may be suitable for the research of osteoporosis, craniofacial and appendicular skeletal defects and for targeted bone regeneration [2].
    PF-4618433
  • HY-109084
    Conteltinib

    CT-707

    		 FAK Cancer
    Conteltinib (CT-707) is a multi-kinase inhibitor targeting FAK, ALK, and Pyk2. Conteltinib exerts significant inhibitory effect on FAK with an IC50 of 1.6 nM .
    Conteltinib
  • HY-10458
    PF-562271 besylate
    Maximum Cited Publications
    30 Publications Verification

    VS-6062 besylate

    		 FAK Pyk2 Cancer
    PF-562271 (VS-6062) besylate is a potent ATP-competitive, reversible inhibitor of FAK and Pyk2 kinase, with an IC50 of 1.5 nM and 13 nM, respectively .
    PF-562271 besylate
  • HY-113788
    PF-719

    		Pyk2 p38 MAPK Amyloid-β Neurological Disease Inflammation/Immunology
    PF-719 is a highly selective Pyk2 inhibitor with an IC50 value of 17 nM. PF-719 promotes the activation of LKB1 and p38 MAPK. PF-719 blocks synaptic deficits induced by Amyloid-beta oligomers and reverses the inhibition of long-term potentiation induced by β-amyloid oligomers. PF-719 can be used in research related to Alzheimer's disease and autoimmune diseases [2] .
    PF-719
  • HY-109082
    Cevidoplenib

    SKI-O-703

    		 Syk Inflammation/Immunology
    Cevidoplenib (SKI-O-703) is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases with IC50s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively [2] .
    Cevidoplenib
  • HY-401485
    Pyk2-IN-2

    		Pyk2 FAK Cancer
    Pyk2-IN-2 (compound 13j) is an inhibitor of Pyk2 with an IC50 of FAK kinase of 0.608 μM .
    Pyk2-IN-2
  • HY-20403
    PF-562271 hydrochloride
    25+ Cited Publications

    VS-6062hydrochloride

    		 FAK Pyk2 Cancer
    PF-562271 (VS-6062) hydrochloride is a potent, ATP-competitive and reversible FAK and Pyk2 kinase inhibitor with IC50s of 1.5 nM and 13 nM, respectively .
    PF-562271 hydrochloride
  • HY-109084A
    Conteltinib tetrahydrochloride

    CT-707 tetrahydrochloride

    		 FAK Cancer
    Conteltinib tetrahydrochloride (CT-707 tetrahydrochloride) is the tetrahydrochloride salt form of Conteltinib (HY-109084). Conteltinib tetrahydrochloride is the inhibitor for FAK (IC50=1.6 nM), ALK, and Pyk2. Conteltinib tetrahydrochloride exhibits a synergistic anti-tumor efficacy with Cabozantinib (HY-13016) .
    Conteltinib tetrahydrochloride
  • HY-178969
    GZD-257

    		FAK Pyk2 Apoptosis Neurological Disease Cancer
    GZD-257 is a brain-penetrant, ATP-competitive FAK inhibitor (IC50 = 14.3 nM), performing 4.77-fold selectivity with FAK to Pyk2 (IC50 = 68.2 nM). GZD-257 can significantly induce apoptosis of U118MG cells and arrest the cell cycle at the G2/M phase. GZD-257 can be used for the study of Glioblastoma (GBM) .
    GZD-257
  • HY-169953
    BT-Amide

    		Pyk2 Metabolic Disease
    BT-Amide is the orally active inhibitor for Pyk2 kinase with IC50 of 44.69 nM. BT-Amide prevents glucocorticoid-induced bone loss, exhibits bone protective activity in C57BL/6 mouse .
    BT-Amide
  • HY-13203R
    NVP-TAE 226 (Standard)

    TAE226 (Standard)

    		 FAK Pyk2 IGF-1R Insulin Receptor Apoptosis Reference Standards Endocrinology Cancer
    NVP-TAE 226 (Standard) is the analytical standard of NVP-TAE 226. This product is intended for research and analytical applications. NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual FAK and IGF-1R inhibitor with IC50s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits Pyk2 and insulin receptor (InsR) with IC50s of 3.5 nM and 44 nM, respectively [2].
    NVP-TAE 226 (Standard)
  • HY-18909
    Multi-kinase-IN-11

    		Src Bcr-Abl Pyk2 p38 MAPK c-Kit Others
    Multi-kinase-IN-11 (Compound 1a) is a DFG-out conformation-targeted multi-kinase inhibitor, including SRC, LCK, ABL, PYK2, CSK, HCK, P38 and C-KIT. Multi-kinase-IN-11 serves as a scaffold for the preparation of fluorescently labeled binding probes and affinity matrices .
    Multi-kinase-IN-11
  • HY-10458R
    PF-562271 besylate (Standard)

    VS-6062 besylate (Standard)

    		 Reference Standards FAK Pyk2 Cancer
    PF-562271 besylate (Standard) is the analytical standard of PF-562271 besylate (HY-10458). This product is intended for research and analytical applications. PF-562271 (VS-6062) besylate is a potent ATP-competitive, reversible inhibitor of FAK and Pyk2 kinase, with an IC50 of 1.5 nM and 13 nM, respectively .
    PF-562271 besylate (Standard)
  • HY-10459R
    PF-562271 (Standard)

    VS-6062 (Standard)

    		 Reference Standards FAK Pyk2 Cancer
    PF-562271 (Standard) is the analytical standard of PF-562271 (HY-10459). This product is intended for research and analytical applications. PF-562271 (VS-6062) is a potent, ATP-competitive and reversible FAK and Pyk2 kinase inhibitor with IC50s of 1.5 nM and 13 nM, respectively .
    PF-562271 (Standard)
  • HY-15322A
    (rel)-PRT062607

    (rel)-P505-15; (rel)-PRT-2607; (rel)-BIIB-057

    		 Syk Drug Isomer Inflammation/Immunology
    (rel)-PRT062607 ((rel)-P505-15) is the relative configuration of PRT062607 (HY-15322). PRT062607 is a highly selective inhibitor of Syk kinase, with an IC50 value of 1-2 nM, and is more than 80 times less potent against Fgr, Lyn, FAK, Pyk2, and Zap70.
    (rel)-PRT062607
  • HY-10460R
    PF-431396 (Standard)

    		Reference Standards Pyk2 FAK Cancer
    PF-431396 (Standard) is the analytical standard of PF-431396 (HY-10460). This product is intended for research and analytical applications. PF-431396 is an orally active dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor, with IC50 values of 2 nM and 11 nM, respectively [2] .
    PF-431396 (Standard)
  • HY-RS20473
    Ptk2b Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ptk2b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ptk2b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ptk2b Mouse Pre-designed siRNA Set A
    Ptk2b Mouse Pre-designed siRNA Set A
  • HY-RS11402
    PTK2B Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    PTK2B Human Pre-designed siRNA Set A contains three designed siRNAs for PTK2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PTK2B Human Pre-designed siRNA Set A
    PTK2B Human Pre-designed siRNA Set A
  • HY-RS26981
    Ptk2b Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ptk2b Rat Pre-designed siRNA Set A contains three designed siRNAs for Ptk2b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ptk2b Rat Pre-designed siRNA Set A
    Ptk2b Rat Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: